Kerstin Unterschemmann

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

Sven Golfier, Charlotte Kopitz, Antje Kahnert et al. · Molecular Cancer Therapeutics · 2014 · 253 citations

Medicine, Oncology, Pharmacology +17

<scp>BAY</scp> 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I

Peter Ellinghaus, Iring Heisler, Kerstin Unterschemmann et al. · Cancer Medicine · 2013 · 226 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

BAY 87–2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts

L. Helbig, Lydia Koi, Kerstin Brüchner et al. · Radiation Oncology · 2014 · 69 citations · Full text

Medicine, Oncology, Pharmacology +16

18F-FAZA PET Imaging Response Tracks the Reoxygenation of Tumors in Mice upon Treatment with the Mitochondrial Complex I Inhibitor BAY 87-2243

Edwin Chang, Hongguang Liu, Kerstin Unterschemmann et al. · Clinical Cancer Research · 2014 · 38 citations · Full text

Medicine, Nuclear Medicine, Pharmacology +17

Hypoxia-Inducible Factor Pathway Inhibition Resolves Tumor Hypoxia and Improves Local Tumor Control After Single-Dose Irradiation

L. Helbig, Lydia Koi, Kerstin Brüchner et al. · International Journal of Radiation Oncology*Biology*Physics · 2013 · 32 citations

Medicine, Cancer Biology, Oncology +14